Literature DB >> 15331061

The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease.

Arthur J McCullough1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) has emerged as the most common chronic liver disease in the United States. The histologic spectrum of NAFLD ranges from steatosis liver alone to nonalcoholic steatohepatitis (NASH), which is the most serious form of NAFLD. NASH is a progressive fibrotic disease, in which cirrhosis and liver-related death occur in up to 20% and 12%, respectively, over a 10-year period. NASH-associated cirrhosis also can develop into subacute liver failure, progress to hepatocellular carcinoma, and reoccur post-transplantation. In contrast, steatosis alone has a more benign clinical course, although progression to cirrhosis has occurred in 3% of these patients. The major risk factors for fibrosis include diabetes or obesity, an aspartate aminotransferase/alanine aminotransferase ratio of greater than 1, age older than 50, and hepatic histology.

Entities:  

Mesh:

Year:  2004        PMID: 15331061     DOI: 10.1016/j.cld.2004.04.004

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  179 in total

1.  Non-alcoholic fatty liver disease: is iron relevant?

Authors:  Julia O'Brien; Lawrie W Powell
Journal:  Hepatol Int       Date:  2011-08-12       Impact factor: 6.047

Review 2.  Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease.

Authors:  Tannaz Eslamparast; Sareh Eghtesad; Hossein Poustchi; Azita Hekmatdoost
Journal:  World J Hepatol       Date:  2015-02-27

3.  Docosahexaenoic acid attenuates Western diet-induced hepatic fibrosis in Ldlr-/- mice by targeting the TGFβ-Smad3 pathway.

Authors:  Kelli A Lytle; Christopher M Depner; Carmen P Wong; Donald B Jump
Journal:  J Lipid Res       Date:  2015-08-27       Impact factor: 5.922

Review 4.  Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

Authors:  Donald B Jump; Kelli A Lytle; Christopher M Depner; Sasmita Tripathy
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

Review 5.  Measurement of liver fat fraction and iron with MRI and MR spectroscopy techniques.

Authors:  Puneet Sharma; Maria Altbach; Jean-Philippe Galons; Bobby Kalb; Diego R Martin
Journal:  Diagn Interv Radiol       Date:  2014 Jan-Feb       Impact factor: 2.630

6.  Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C.

Authors:  Atsushi Tanaka; Satoko Uegaki; Hiroko Kurihara; Kiyoshi Aida; Masaki Mikami; Ikuo Nagashima; Junji Shiga; Hajime Takikawa
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

7.  Laparoscopic bariatric surgery: what else are we uncovering? Liver pathology and preoperative indicators of advanced liver disease in morbidly obese patients.

Authors:  Matthew Kroh; Rockson Liu; Bipan Chand
Journal:  Surg Endosc       Date:  2007-05-04       Impact factor: 4.584

8.  Respiratory motion-corrected proton magnetic resonance spectroscopy of the liver.

Authors:  Susan M Noworolski; Phyllis C Tien; Raphael Merriman; Daniel B Vigneron; Aliya Qayyum
Journal:  Magn Reson Imaging       Date:  2008-11-06       Impact factor: 2.546

9.  Kupffer cell activation by ambient air particulate matter exposure may exacerbate non-alcoholic fatty liver disease.

Authors:  Hui-Hui Tan; M Isabel Fiel; Qinghua Sun; Jinsheng Guo; Ronald E Gordon; Lung-Chi Chen; Scott L Friedman; Joseph A Odin; Jorge Allina
Journal:  J Immunotoxicol       Date:  2009-12       Impact factor: 3.000

10.  Sodium acetate improves disrupted glucoregulation and hepatic triglyceride content in insulin-resistant female rats: involvement of adenosine deaminase and dipeptidyl peptidase-4 activities.

Authors:  Tolulope Eniola Omolekulo; Olugbenga Samuel Michael; Lawrence Aderemi Olatunji
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-10-02       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.